Oral Small Molecule Therapeutics
•254 stocks
•
Total Market Cap: Loading...
Apr 17, 2026
|
Kura Oncology Reports Robust Activity of Darlifarnib Plus Cabozantinib in Cabozantinib‑Pretreated Renal Cell Carcinoma
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (254)
| Company | Market Cap | Price |
|---|---|---|
|
OMER
Omeros Corporation
Pipeline includes oral small-molecule therapeutics in addition to biologics.
|
$958.91M |
$13.94
-1.10%
|
|
PHAT
Phathom Pharmaceuticals, Inc.
VOQUEZNA (vonoprazan) is an oral small-molecule therapeutic (P-CAB) with GERD and H. pylori indications, representing the company’s core product line.
|
$938.32M |
$13.19
+4.56%
|
|
ABUS
Arbutus Biopharma Corporation
AB-101 is described as an oral small-molecule PD-L1 inhibitor, representing an oral small molecule therapeutics product line.
|
$907.77M |
$4.71
+0.75%
|
|
CGEM
Cullinan Therapeutics, Inc.
Zipalertinib is an orally administered small-molecule EGFR inhibitor targeting ex20ins NSCLC.
|
$889.69M |
$15.03
+1.97%
|
|
TBPH
Theravance Biopharma, Inc.
Ampreloxetine is an oral small-molecule therapeutic in Phase 3 (CYPRESS) for symptomatic nOH in MSA, representing a core TBPH pipeline asset.
|
$873.09M |
$17.23
+2.68%
|
|
ANRO
Alto Neuroscience, Inc.
ALTO-300 is an oral small molecule therapeutic (melatonin receptor agonist/5-HT2C antagonist), a major product category.
|
$861.16M |
$27.64
+6.04%
|
|
KURA
Kura Oncology, Inc.
Ziftomenib and KO-2806 are oral small molecule therapeutics, fitting the Oral Small Molecule Therapeutics category.
|
$842.33M |
$9.69
+8.33%
|
|
IVA
Inventiva S.A.
Inventiva's lanifibranor is an orally administered small-molecule therapeutic for MASH, fitting the 'Oral Small Molecule Therapeutics' tag.
|
$788.99M |
$5.68
+0.98%
|
|
GYRE
Gyre Therapeutics, Inc.
Gyre Therapeutics develops and commercializes small-molecule therapeutics (lead Hydronidone/F351 and multiple pipeline agents, plus licensed products) for fibrotic diseases, which fits the 'Oral Small Molecule Therapeutics' category.
|
$780.30M |
$8.12
+2.78%
|
|
DSGN
Design Therapeutics, Inc.
Company develops small-molecule therapeutics (GeneTAC) targeting inherited nucleotide repeat disorders.
|
$747.36M |
$13.12
+4.88%
|
|
SLS
SELLAS Life Sciences Group, Inc.
SLS009 (tambiciclib) is a small-molecule CDK9 inhibitor, qualifying as Oral Small Molecule Therapeutics.
|
$743.55M |
$5.24
+6.19%
|
|
ARVN
Arvinas, Inc.
Vepdegestrant is an oral small-molecule degrader; the pipeline centers on oral small-molecule degraders, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$706.47M |
$10.97
-0.23%
|
|
DRUG
Bright Minds Biosciences Inc.
Developing small-molecule therapeutics (5-HT receptor agonists), a major drug class.
|
$686.46M |
$89.61
+1.08%
|
|
LXRX
Lexicon Pharmaceuticals, Inc.
Lexicon's pipeline includes oral small-molecule therapeutics pilavapadin (LX9211) and LX9851; these are oral small-molecule drugs, a major product category in their portfolio.
|
$679.56M |
$1.89
+2.72%
|
|
ETON
Eton Pharmaceuticals, Inc.
KHINDIVI (ET-400), ET-600, ET-700, and ET-800 involve oral/ready formulations (e.g., desmopressin, hydrocortisone, zinc) consistent with the Oral Small Molecule Therapeutics category.
|
$671.51M |
$25.05
+2.52%
|
|
BIOA
BioAge Labs, Inc.
BioAge's lead program BGE-102 is an oral small-molecule therapeutic, and APJ agonists are being developed for obesity, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$662.96M |
$18.48
+8.77%
|
|
RIGL
Rigel Pharmaceuticals, Inc.
All approved and development-stage oral agents (fostamatinib, olutasidenib, pralsetinib, R289) are delivered orally, aligning with Oral Small Molecule Therapeutics.
|
$588.65M |
$32.39
+1.95%
|
|
CRMD
CorMedix Inc.
MINOCIN is an oral small-molecule antibiotic, reflecting an oral antibiotic product line.
|
$582.25M |
$7.39
+3.65%
|
|
AQST
Aquestive Therapeutics, Inc.
Anaphylm's oral small-molecule epinephrine film and AQST-108 (epinephrine topical gel) indicate a focus on oral small-molecule therapeutics delivered via film/topical formats.
|
$527.05M |
$4.33
+1.64%
|
|
ANNX
Annexon, Inc.
ANX1502 is an oral small molecule inhibitor, categorized under Oral Small Molecule Therapeutics.
|
$515.37M |
$4.67
-6.87%
|
|
ESPR
Esperion Therapeutics, Inc.
Oral small-molecule LDL-C lowering therapies (NEXLETOL/NEXLIZET).
|
$487.69M |
$2.04
-0.73%
|
|
ZVRA
Zevra Therapeutics, Inc.
KP1077 and OLPRUVA are oral small molecule therapies (prodrugs); Zevra's pipeline includes oral small-molecule therapeutics.
|
$466.48M |
$8.48
+2.05%
|
|
ASMB
Assembly Biosciences, Inc.
Pipeline products are administered orally, classifying the company under oral small-molecule therapeutics as a core product modality.
|
$462.49M |
$29.10
-0.75%
|
|
ACRS
Aclaris Therapeutics, Inc.
ATI-2138 is an oral small-molecule therapeutic (ITK/JAK3 inhibitor), aligning with Oral Small Molecule Therapeutics.
|
$460.47M |
$4.25
+6.78%
|
|
FULC
Fulcrum Therapeutics, Inc.
Fulcrum's lead asset pociredir is an oral small molecule therapeutic intended to induce HbF in SCD.
|
$448.64M |
$8.29
+3.82%
|
|
AVIR
Atea Pharmaceuticals, Inc.
The company is developing an oral fixed-dose combination regimen of bemnifosbuvir and ruzasvir for HCV, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$448.45M |
$5.74
+0.61%
|
|
VSTM
Verastem, Inc.
Lead products are oral small-molecule inhibitors (avutometinib, defactinib) used in combination therapy, fitting the 'Oral Small Molecule Therapeutics' category.
|
$439.39M |
$6.58
+3.71%
|
|
PRTC
PureTech Health plc
LYT-100 is an oral small-molecule therapeutic for IPF.
|
$438.14M |
$18.09
-0.71%
|
|
VNDA
Vanda Pharmaceuticals Inc.
Fanapt and other marketed/potential small-molecule therapies (e.g., Tradipitant) are oral small molecule therapeutics.
|
$429.63M |
$7.26
+1.47%
|
|
ENTA
Enanta Pharmaceuticals, Inc.
Lead RSV programs (zelicapavir and EDP-323) are oral small-molecule therapeutics, aligning with the Oral Small Molecule Therapeutics theme.
|
$404.37M |
$14.01
-0.39%
|
|
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
Lead programs are oral small-molecule therapeutics targeting NI&I indications.
|
$394.84M |
$13.54
+1.80%
|
|
ITOS
iTeos Therapeutics, Inc.
EOS-984 ENT1 inhibitor and other small-molecule assets indicate development or use of oral small molecule therapeutics.
|
$388.48M |
$10.15
|
|
MNPR
Monopar Therapeutics Inc.
ALXN1840 is an oral small-molecule therapeutic for Wilson disease, aligning with Oral Small Molecule Therapeutics.
|
$380.87M |
$56.59
-8.33%
|
|
PBYI
Puma Biotechnology, Inc.
Neratinib and alisertib are oral small-molecule therapeutics, indicating a major category of oral oncology drugs.
|
$376.42M |
$7.47
+3.18%
|
|
VIGL
Vigil Neuroscience, Inc.
VG-3927 is an oral small molecule TREM2 agonist, placing Vigil's small-molecule therapeutic program under Oral Small Molecule Therapeutics.
|
$375.71M |
$8.05
|
|
XFOR
X4 Pharmaceuticals, Inc.
Mavorixafor is an oral small-molecule therapeutic agent.
|
$375.10M |
$4.27
+3.14%
|
|
AKBA
Akebia Therapeutics, Inc.
Vafseo (vadadustat) is Akebia's core product, an oral small-molecule therapeutic (HIF-PHI) for CKD anemia, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$372.84M |
$1.41
+4.07%
|
|
NMRA
Neumora Therapeutics, Inc. Common Stock
Navacaprant is an oral small-molecule therapeutic, aligning with Oral Small Molecule Therapeutics.
|
$359.24M |
$2.15
+7.50%
|
|
IMRX
Immuneering Corporation
Atebimetinib (IMM-1-104) is an oral small-molecule therapeutic in clinical trials.
|
$359.01M |
$5.55
-0.27%
|
|
PALI
Palisade Bio, Inc.
PALI-2108 is an orally administered small molecule therapeutic, matching the Oral Small Molecule Therapeutics tag.
|
$357.61M |
$2.40
+2.79%
|
|
SIGA
SIGA Technologies, Inc.
TPOXX is available in an oral formulation, placing SIGA in the Oral Small Molecule Therapeutics category.
|
$340.87M |
$4.75
+2.26%
|
|
ZNTL
Zentalis Pharmaceuticals, Inc.
Azenosertib is an oral small-molecule inhibitor, making this a direct major product category for the company.
|
$335.24M |
$4.62
-7.97%
|
|
AVXL
Anavex Life Sciences Corp.
Company's lead product and pipeline consist of oral small-molecule therapeutics (ANAVEX 2-73 and ANAVEX 3-71).
|
$325.23M |
$3.63
+6.91%
|
|
AMRN
Amarin Corporation plc
Icosapent ethyl is administered orally as a lipid-lowering therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$304.32M |
$14.91
+1.29%
|
|
ACIU
AC Immune S.A.
Oral Small Molecule Therapeutics – Morphomer platform developing small-molecule inhibitors (e.g., Tau aggregation, alpha-synuclein) for neurodegeneration.
|
$303.69M |
$3.00
-2.12%
|
|
FHTX
Foghorn Therapeutics Inc.
FHD-909 is a selective oral small-molecule inhibitor; pipeline includes additional oral small-molecule therapeutics.
|
$299.16M |
$5.29
+8.95%
|
|
CCCC
C4 Therapeutics, Inc.
Lead assets (e.g., cemsidomide) are orally bioavailable small-molecule degraders, fitting the 'Oral Small Molecule Therapeutics' category.
|
$282.99M |
$2.92
+0.69%
|
|
PRLD
Prelude Therapeutics Incorporated
Lead programs include oral small-molecule degraders (e.g., SMARCA2 degraders, KAT6A degrader, CDK9 inhibitor), classifying them under Oral Small Molecule Therapeutics.
|
$279.12M |
$4.46
+0.56%
|
|
ACHV
Achieve Life Sciences, Inc.
Cytisinicline is an oral small-molecule therapeutic candidate for smoking cessation, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$271.49M |
$5.11
+6.13%
|
|
ANL
Adlai Nortye Ltd.
The company’s pipeline includes oral small-molecule therapeutics (e.g., AN4005, AN9025), aligning with the Oral Small Molecule Therapeutics category.
|
$238.14M |
$6.53
-3.26%
|
|
NVCT
Nuvectis Pharma, Inc.
NXP900 is described with oral dosing (mg/day), supporting the tag 'Oral Small Molecule Therapeutics'.
|
$227.97M |
$8.86
+6.11%
|
|
SGMT
Sagimet Biosciences Inc.
Sagimet's lead and second FASN inhibitors (denifanstat, TVB-3567) are oral small-molecule therapeutics, directly aligning with this tag.
|
$210.41M |
$6.47
+4.60%
|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
CRB-913 is an oral small molecule CB1 inverse agonist aimed at obesity; classifies as an oral small molecule therapeutic.
|
$185.89M |
$10.59
+4.39%
|
|
BDTX
Black Diamond Therapeutics, Inc.
BDTX-1535 is a brain-penetrant, fourth-generation EGFR inhibitor, representing an oral small molecule therapeutic.
|
$174.34M |
$3.07
+5.14%
|
|
TNXP
Tonix Pharmaceuticals Holding Corp.
TNX-102 SL is Tonix's lead oral small-molecule drug for fibromyalgia (cyclobenzaprine HCl sublingual), a direct product the company develops and plans to bring to market.
|
$164.64M |
$13.96
-1.17%
|
|
GALT
Galectin Therapeutics Inc.
The company is pursuing a small molecule oral galectin-3 inhibitor program via Galectin Sciences LLC, representing an Oral Small Molecule Therapeutics pathway.
|
$157.96M |
$2.44
+8.19%
|
|
BMEA
Biomea Fusion, Inc.
Direct product category: Biomea Fusion is developing oral small molecule therapeutics, including icovamenib and BMF-650.
|
$156.26M |
$2.21
+14.25%
|
|
SPRO
Spero Therapeutics, Inc.
Tebipenem HBr is an oral small-molecule antibiotic, which is the lead product and central to Spero’s current business focus.
|
$154.93M |
$2.75
+2.61%
|
|
SAVA
Cassava Sciences, Inc.
Direct product category: simufilam is developed as an oral small-molecule therapeutic.
|
$154.10M |
$3.23
+1.10%
|
|
VTVT
vTv Therapeutics Inc.
Cadisegliatin is an oral, small-molecule therapeutic developed by the company for Type 1 Diabetes, directly matching the 'Oral Small Molecule Therapeutics' category.
|
$150.13M |
$37.73
+2.65%
|
|
KPTI
Karyopharm Therapeutics Inc.
Selinexor is an oral small molecule therapeutic; the company emphasizes oral regimens and late-stage oral therapies in MF and EC, constituting a major product category.
|
$146.81M |
$8.60
-0.75%
|
|
DERM
Journey Medical Corporation
Emrosi is an oral small molecule therapeutic (minocycline extended-release) and represents Journey Medical's flagship product launched in 2025.
|
$146.26M |
$5.39
+4.26%
|
|
IKT
Inhibikase Therapeutics, Inc.
IKT's lead program IKT-001Pro is an oral small-molecule therapeutic prodrug, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$137.57M |
$1.81
+6.76%
|
|
TNYA
Tenaya Therapeutics, Inc.
TN-301 is an oral small-molecule HDAC6 inhibitor, qualifying as Oral Small Molecule Therapeutics.
|
$130.22M |
$0.78
+4.87%
|
|
EQ
Equillium, Inc.
EQ302 is described as an oral, bispecific inhibitor, fitting the Oral Small Molecule Therapeutics category.
|
$124.83M |
$2.05
+3.54%
|
|
CRDF
Cardiff Oncology, Inc.
Onvansertib is an oral small-molecule therapeutic, representing the company's primary product modality.
|
$121.25M |
$1.80
+6.80%
|
|
ASRT
Assertio Holdings, Inc.
Sympazan is an oral small-molecule therapeutic delivered as a film, fitting the Oral Small Molecule Therapeutics category.
|
$115.57M |
$18.02
|
|
AARD
Aardvark Therapeutics, Inc. Common Stock
ARD-101 and ARD-201 are oral small-molecule therapeutics targeting satiety pathways for metabolic and rare-disease indications.
|
$113.87M |
$5.24
+5.01%
|
|
RPTX
Repare Therapeutics Inc.
RP-1664 is an oral small-molecule PLK4 inhibitor, indicating a major product category of oral small-molecule therapeutics.
|
$113.84M |
$2.65
-0.19%
|
|
ALDX
Aldeyra Therapeutics, Inc.
ADX-629 is an oral RASP modulator, classed as oral small molecule therapeutics.
|
$108.29M |
$1.81
+0.56%
|
|
IFRX
InflaRx N.V.
INF904 is an oral small-molecule C5aR antagonist, representing a major Oral Small Molecule Therapeutics program.
|
$107.72M |
$1.59
+32.50%
|
|
UNCY
Unicycive Therapeutics, Inc.
Lead programs Oxylanthanum Carbonate (OLC) and UNI-494 are oral small-molecule therapeutics targeting kidney disease and hyperphosphatemia/acute kidney injury.
|
$106.15M |
$6.21
+3.41%
|
|
CGTX
Cognition Therapeutics, Inc.
CT1812 (zervimesine) is an orally delivered small-molecule therapeutic, the core product of the company.
|
$105.05M |
$1.20
+7.66%
|
|
ACOG
Alpha Cognition Inc. Common Stock
ZUNVEYL is an oral small molecule therapeutic for Alzheimer's disease.
|
$105.05M |
$6.50
+5.18%
|
|
NTHI
Neonc Technologies Holdings, Inc.
NEO212 is an oral small molecule therapeutic being developed for brain tumors.
|
$103.99M |
$5.29
+5.38%
|
|
CRDL
Cardiol Therapeutics Inc.
CardiolRx is an oral small-molecule therapeutic.
|
$103.34M |
$1.24
+11.71%
|
|
GOSS
Gossamer Bio, Inc.
Seralutinib is a small molecule therapeutic, classifying under small molecule therapeutics in the existing taxonomy.
|
$103.23M |
$0.44
+1.60%
|
|
ANTX
AN2 Therapeutics, Inc.
Epetraborole and AN2-502998 are oral small-molecule therapeutics developed on the company's boron chemistry platform.
|
$98.92M |
$3.61
+14.97%
|
|
PLRX
Pliant Therapeutics, Inc.
Company's lead and mid-stage assets include oral small-molecule therapeutics (bexotegrast and PLN-101095) targeting integrin pathways.
|
$81.73M |
$1.34
+3.46%
|
|
ATHE
Alterity Therapeutics Limited
ATH434 is a small-molecule oral therapeutic in clinical development (Phase 2) for neurodegenerative disease, identified as Alterity's lead product.
|
$81.60M |
$4.34
+9.32%
|
|
GANX
Gain Therapeutics, Inc.
GT-02287 is a small-molecule therapeutic candidate, aligning with the major product category of oral small-molecule therapeutics.
|
$76.89M |
$2.14
+4.39%
|
|
FBIO
Fortress Biotech, Inc.
Emrosi is a modified-release oral antibiotic (minocycline), placing Fortress in the Oral Small Molecule Therapeutics category via its portfolio.
|
$73.25M |
$2.35
+0.21%
|
|
NRXP
NRx Pharmaceuticals, Inc.
NRX-101 is an oral small-molecule therapeutic (D-cycloserine + lurasidone) for bipolar depression.
|
$71.65M |
$2.56
+1.99%
|
|
MNOV
MediciNova, Inc.
MN-166 (ibudilast) and MN-001 (tipelukast) are oral small-molecule therapeutics in MediciNova's development pipeline.
|
$71.61M |
$1.45
+0.69%
|
|
BYSI
BeyondSpring Inc.
Plinabulin is a small-molecule therapeutic; categorize under Oral Small Molecule Therapeutics.
|
$69.77M |
$1.68
|
|
IMUX
Immunic, Inc.
Immunic's lead programs are oral, small-molecule therapeutics (e.g., vidofludimus calcium and IMU-856).
|
$68.07M |
$0.69
+0.07%
|
|
IBO
Impact BioMedical Inc.
Linebacker/Equivir are small-molecule therapeutics with potential oral administration pathways, aligning with Oral Small Molecule Therapeutics.
|
$67.48M |
$0.62
-5.97%
|
|
CLNN
Clene Inc.
CNM-Au8 is the lead asset pursued as a therapeutic, likely administered orally as a small-molecule/low-molecular-weight product.
|
$65.21M |
$6.40
+0.79%
|
|
GRCE
Grace Therapeutics, Inc.
GTx-102.00 is a betamethasone oral-mucosal spray, representing an oral small-molecule therapeutic asset.
|
$60.61M |
$4.29
+4.13%
|
|
DRRX
DURECT Corporation
Larsucosterol is described as an orally bioavailable small molecule therapeutic and the lead program for DURECT, targeting alcohol-associated hepatitis.
|
$59.29M |
$1.91
|
|
ACRV
Acrivon Therapeutics, Inc. Common Stock
Oral Small Molecule Therapeutics: ACR-368 and ACR-2316 are oral small-molecule inhibitors (CHK1/CHK2 and WEE1/PKMYT1).
|
$56.17M |
$1.77
+6.29%
|
|
ACTU
Actuate Therapeutics Inc
Elraglusib includes oral tablet formulation development, aligning with the Oral Small Molecule Therapeutics category.
|
$53.69M |
$2.29
+6.74%
|
|
KRON
Kronos Bio, Inc.
The company's lead assets are small-molecule therapeutics (e.g., istisociclib), indicating a focus on Oral Small Molecule Therapeutics.
|
$53.65M |
$0.88
|
|
MREO
Mereo BioPharma Group plc
Alvelestat is an oral small-molecule therapeutic, aligning with Oral Small Molecule Therapeutics.
|
$53.56M |
$0.33
+2.64%
|
|
ATOS
Atossa Therapeutics, Inc.
Z-endoxifen is an oral small-molecule therapeutic, and Atossa is prioritizing its metastatic breast cancer indication, representing a major product category.
|
$50.20M |
$5.90
+2.25%
|
|
TELO
Telomir Pharmaceuticals, Inc. Common Stock
Telomir-1 is described as an oral small molecule therapeutic candidate, directly matching the 'Oral Small Molecule Therapeutics' tag.
|
$49.85M |
$1.46
+8.96%
|
|
ANVS
Annovis Bio, Inc.
Buntanetap is described as an orally administered small molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$49.56M |
$1.89
+5.90%
|
|
CPIX
Cumberland Pharmaceuticals Inc.
Ifetroban is a small-molecule therapeutic candidate, categorized as an oral small-molecule therapeutic if applicable.
|
$48.31M |
$3.25
+5.18%
|
|
NERV
Minerva Neurosciences, Inc.
Roluperidone is an oral small-molecule therapeutic candidate, a core product type.
|
$47.07M |
$6.73
+7.00%
|
|
SCYX
SCYNEXIS, Inc.
SCYNEXIS's ibrexafungerp is a lead oral small-molecule therapeutic, fitting the 'Oral Small Molecule Therapeutics' category.
|
$46.58M |
$1.10
+4.76%
|
Showing page 2 of 3 (254 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
